Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
AEZS's Cash to Debt is ranked higher than
98% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. AEZS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AEZS' s Cash to Debt Range Over the Past 10 Years
Min: 0.44  Med: 137.57 Max: No Debt
Current: No Debt
Equity to Asset 0.24
AEZS's Equity to Asset is ranked lower than
85% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AEZS: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
AEZS' s Equity to Asset Range Over the Past 10 Years
Min: -0.34  Med: 0.37 Max: 0.98
Current: 0.24
-0.34
0.98
Interest Coverage No Debt
AEZS's Interest Coverage is ranked higher than
97% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AEZS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AEZS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -12.59
M-Score: -2.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -5162.00
AEZS's Operating margin (%) is ranked lower than
89% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. AEZS: -5162.00 )
Ranked among companies with meaningful Operating margin (%) only.
AEZS' s Operating margin (%) Range Over the Past 10 Years
Min: -339954.55  Med: -303.55 Max: -37.89
Current: -5162
-339954.55
-37.89
Net-margin (%) -5892.56
AEZS's Net-margin (%) is ranked lower than
91% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. AEZS: -5892.56 )
Ranked among companies with meaningful Net-margin (%) only.
AEZS' s Net-margin (%) Range Over the Past 10 Years
Min: -150581.82  Med: -129.08 Max: 110.36
Current: -5892.56
-150581.82
110.36
ROE (%) -261.83
AEZS's ROE (%) is ranked lower than
95% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. AEZS: -261.83 )
Ranked among companies with meaningful ROE (%) only.
AEZS' s ROE (%) Range Over the Past 10 Years
Min: -703.16  Med: -128.07 Max: 125.8
Current: -261.83
-703.16
125.8
ROA (%) -76.71
AEZS's ROA (%) is ranked lower than
81% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. AEZS: -76.71 )
Ranked among companies with meaningful ROA (%) only.
AEZS' s ROA (%) Range Over the Past 10 Years
Min: -109.74  Med: -30.25 Max: 11.16
Current: -76.71
-109.74
11.16
ROC (Joel Greenblatt) (%) -11702.89
AEZS's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. AEZS: -11702.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AEZS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11702.89  Med: -917.48 Max: -34.36
Current: -11702.89
-11702.89
-34.36
Revenue Growth (3Y)(%) -72.30
AEZS's Revenue Growth (3Y)(%) is ranked lower than
90% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. AEZS: -72.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AEZS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -23.1 Max: 131.2
Current: -72.3
0
131.2
EBITDA Growth (3Y)(%) -49.50
AEZS's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AEZS: -49.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AEZS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -18.7 Max: 183.9
Current: -49.5
0
183.9
EPS Growth (3Y)(%) -40.10
AEZS's EPS Growth (3Y)(%) is ranked lower than
86% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. AEZS: -40.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AEZS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -19.85 Max: 64.9
Current: -40.1
0
64.9
» AEZS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

AEZS Guru Trades in Q3 2015

Jim Simons 11,284,993 sh (+255.23%)
» More
Q4 2015

AEZS Guru Trades in Q4 2015

Jim Simons 487,833 sh (-95.68%)
» More
Q1 2016

AEZS Guru Trades in Q1 2016

Jim Simons 516,833 sh (+5.94%)
» More
Q2 2016

AEZS Guru Trades in Q2 2016

Jim Simons 445,333 sh (-13.83%)
» More
» Details

Insider Trades

Latest Guru Trades with AEZS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:VTGN, NAS:ICCC, OTCPK:ONCYF, OTCPK:PTGEF, NAS:CLSN, NAS:CUR, OTCPK:QBIO, OTCPK:BNHLF, AMEX:CANF, NAS:ONCS, NAS:CTRV, OTCPK:LVCLY, NAS:TKAI, OTCPK:XBIO, NAS:PZRX, NAS:VICL, OTCPK:PPGNY, OTCPK:ANTB, NAS:ORPN, NAS:CLBS » details
Traded in other countries:AEZ.Canada, ET82.Germany,
AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology, endocrinology and women's health.

AEterna Zentaris Inc is incorporated on September 12, 1990 under the Canada Business Corporations Act (the CBCA) and continues to be governed by the CBCA. The Company is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. Its pipeline encompasses compounds at all stages of development from drug discovery through to marketed products. Its oncology pipeline also encompasses other earlier-stage programs, including AEZS-112, an oral anticancer agent which involves three mechanisms of action such as tubulin, topoisomerase II and angiogenesis inhibition which has completed a Phase 1 trial in advanced solid tumors and lymphoma. Additionally, several novel targeted anticancer candidates such as AEZS-120, a live recombinant oral tumor vaccine candidate, as well as PI3K/Erk inhibitors, including AEZS-129, AEZS-134 and AEZS-136, are currently in preclinical development. In endocrinology, the Company is preparing the filing of an NDA in the U.S. for the registration of AEZS-130, an oral ghrelin agonist, as a diagnostic test for adult growth hormone deficiency (AGHD). A Phase 3 trial under a SPA with the FDA has been completed in this indication. Furthermore, AEZS-130 is in a Phase 2A trial for the treatment of cancer-induced cachexia.

Ratios

vs
industry
vs
history
P/E(ttm) 1.09
AEZS's P/E(ttm) is ranked higher than
96% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. AEZS: 1.09 )
Ranked among companies with meaningful P/E(ttm) only.
AEZS' s P/E(ttm) Range Over the Past 10 Years
Min: 1  Med: 9.16 Max: 21.24
Current: 1.09
1
21.24
PE(NRI) 1.10
AEZS's PE(NRI) is ranked higher than
97% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AEZS: 1.10 )
Ranked among companies with meaningful PE(NRI) only.
AEZS' s PE(NRI) Range Over the Past 10 Years
Min: 1.01  Med: 20.27 Max: 78.86
Current: 1.1
1.01
78.86
P/B 3.87
AEZS's P/B is ranked higher than
50% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. AEZS: 3.87 )
Ranked among companies with meaningful P/B only.
AEZS' s P/B Range Over the Past 10 Years
Min: 0.58  Med: 2.06 Max: 44.27
Current: 3.87
0.58
44.27
P/S 24.66
AEZS's P/S is ranked lower than
67% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. AEZS: 24.66 )
Ranked among companies with meaningful P/S only.
AEZS' s P/S Range Over the Past 10 Years
Min: 0.68  Med: 4.78 Max: 3761.9
Current: 24.66
0.68
3761.9
Current Ratio 5.04
AEZS's Current Ratio is ranked higher than
53% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. AEZS: 5.04 )
Ranked among companies with meaningful Current Ratio only.
AEZS' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 3.35 Max: 50.67
Current: 5.04
0.92
50.67
Quick Ratio 5.04
AEZS's Quick Ratio is ranked higher than
54% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. AEZS: 5.04 )
Ranked among companies with meaningful Quick Ratio only.
AEZS' s Quick Ratio Range Over the Past 10 Years
Min: 0.92  Med: 3.12 Max: 49
Current: 5.04
0.92
49
Days Sales Outstanding 370.94
AEZS's Days Sales Outstanding is ranked lower than
95% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. AEZS: 370.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
AEZS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.11  Med: 81.53 Max: 19345
Current: 370.94
14.11
19345

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -241.20
AEZS's 3-Year Average Share Buyback Ratio is ranked lower than
97% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. AEZS: -241.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AEZS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -241.2  Med: -15.9 Max: 0
Current: -241.2
-241.2
0

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 43.13
AEZS's Price/Tangible Book is ranked lower than
95% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. AEZS: 43.13 )
Ranked among companies with meaningful Price/Tangible Book only.
AEZS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.01  Med: 2.84 Max: 84.69
Current: 43.13
1.01
84.69
Price/Median PS Value 5.23
AEZS's Price/Median PS Value is ranked lower than
93% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. AEZS: 5.23 )
Ranked among companies with meaningful Price/Median PS Value only.
AEZS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 0.97 Max: 690
Current: 5.23
0.13
690
Price/Graham Number 1.42
AEZS's Price/Graham Number is ranked higher than
78% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.74 vs. AEZS: 1.42 )
Ranked among companies with meaningful Price/Graham Number only.
AEZS' s Price/Graham Number Range Over the Past 10 Years
Min: 1.32  Med: 1.63 Max: 2.01
Current: 1.42
1.32
2.01
Earnings Yield (Greenblatt) (%) -374.74
AEZS's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. AEZS: -374.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AEZS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -398.28  Med: 259.3 Max: 23874.8
Current: -374.74
-398.28
23874.8

More Statistics

Revenue (TTM) (Mil) $0.61
EPS (TTM) $ 2.78
Beta1.09
Short Percentage of Float7.21%
52-Week Range $2.60 - 15.70
Shares Outstanding (Mil)9.94

Analyst Estimate

Dec18
Revenue (Mil $)
EPS ($) -0.92
EPS w/o NRI ($) -0.92
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for AEZS

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Keryx Still Has High Potential from Zerenex Apr 12 2012 
Opportunistic Coat-tailing Jan 05 2010 

More From Other Websites
09.14.2016 Aeterna Zentaris Announces Expiration of Remaining Series B Warrants Sep 14 2016
Aeterna Zentaris Announces Expiration of Remaining Series B Warrants Sep 14 2016
Aeterna Zentaris to Present at Upcoming Aegis Capital Corp. 2016 Growth Conference in Las Vegas,... Sep 12 2016
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New... Sep 06 2016
Aeterna Zentaris reports 2Q loss Aug 09 2016
Aeterna Zentaris reports 2Q loss Aug 09 2016
08.09.2016 Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results Aug 09 2016
Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results Aug 09 2016
08.08.2016 Aeterna Zentaris Expands Promotion of APIFINY® into Florida Aug 08 2016
Aeterna Zentaris Expands Promotion of APIFINY® into Florida Aug 08 2016
08.01.2016 Aeterna Zentaris and Rafa Laboratories Sign Exclusive License Agreement for Zoptrex™ in... Aug 01 2016
Aeterna Zentaris and Rafa Laboratories Sign Exclusive License Agreement for Zoptrex™ in Israel Aug 01 2016
07.27.2016 Aeterna Zentaris to Announce Second Quarter 2016 Financial and Operating Results on... Jul 27 2016
Aeterna Zentaris to Announce Second Quarter 2016 Financial and Operating Results on August 9, 2016 Jul 27 2016
07.01.2016 Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for... Jul 01 2016
Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for Zoptrex™ in... Jul 01 2016
Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for Zoptrex™ in... Jul 01 2016
05.23.2016 Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board Jun 16 2016
06.06.2016 Aeterna Zentaris Reconfirms Commitment to LHRH-receptor Targeting Zoptrex™ During 2016... Jun 16 2016
06.14.2016 Aeterna Zentaris Announces IND Submission by Sinopharm A-Think Jun 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)